Kornimate/medical-research-clean huggingface dataset:
cervical traction, passive accessory intervertebral movements and active strength training in cervical radiculopathy

Conditions: Cervical Radiculopathy

Summary: to determine the effectiveness of manual cervical traction, passive accessory intervertebral movements (paivms) and active strength training in the management of cervical radiculopathy. to compare the effectiveness of manual cervical traction, passive accessory intervertebral movements (paivms) and active strength training in the management of cervical radiculopathy.

cervical radiculopathy is a clinical condition resulting from compression of cervical nerve roots near the spinal cord. some factors that may increase the risk for developing cervical radiculopathy include age. the risk for cervical radiculopathy tends to increase with age. this study is based on three interventions (manual cervical traction, passive accessory intervertebral movements (paivms) and active strength training) individually on three separate but equal groups of participants. it will determine the most effective intervention and which intervention is superior to the other for treating cervical radiculopathy and to assist future practitioners and researchers.

Eligibility criteria:
inclusion criteria: * diagnosed with cervical radiculopathy due to muscle tightness or spasm (diagnosed by spurling's test) * having complaint more than 2 months exclusion criteria: * past history of cervical surgery * past history of cervical trauma * any inflammatory disease * tumor or carcinoma * disco genic/ disc herniation or stenosis cause of radiculopathy.
evaluation of cerebral spinal fluid and blood in patients with subarachnoid hemorrhage

Conditions: Subarachnoid Hemorrhage

Summary: in this project we are collecting cerebrospinal fluid and blood from patients at vanderbilt medical center who have a subarachnoid hemorrhage which has followed the rupture of a brain aneurysm. we then propose to study the cerebrospinal fluid using a novel microscopic laser directed mass spectrometric analysis (maldi) available at vanderbilt. the cerebrospinal fluid and blood will then be analysed for different biological markers, protein expression and gene expression. these markers will then be statistically correlated with clinical data including prediction of vasospasm, time to vasospasm and response to standard therapy.

in this project we are collecting cerebrospinal fluid and blood from patients at vanderbilt medical center who have a subarachnoid hemorrhage which has followed the rupture of a brain aneurysm. we then propose to study the cerebrospinal fluid using a novel microscopic laser directed mass spectrometric analysis (maldi) available at vanderbilt. the cerebrospinal fluid and blood will then be analysed for different biological markers, protein expression and gene expression. these markers will then be statistically correlated with clinical data including prediction of vasospasm, time to vasospasm and response to standard therapy. the goal of this study is to determine cerebrospinal fluid and serum markers which will be predictive of vasospasm. this in turn may lead to improved outcomes in this population of patients. the data will be compared to excess cerebrospinal fluid collected from patients who are undergoing lumbar puncture in the neurology clinic or excess cerebrospinal fluid from patients undergoing cranial surgery for other causes like tumor excision. for patients enrolled in the study, cerebrospinal fluid will be collected by either lumbar puncture or external ventricular catheter. specimens will be collected immediately pre-operatively if an external ventricular drain is in place or intraoperatively if an external ventricular drain is not present. we will also collect cerebrospinal fluid post operatively after placement of an external ventricular drain regularly from the excess cerebrospinal fluid that has been collected in the drainage bag. csf will be collected in a serial fashion at multiple time points: immediately post operatively, during vasospasm and before the external ventricular drain is removed.

Eligibility criteria:
inclusion criteria: * patients eligible to participate in this study are those that have a documented subarachnoid hemorrhage from a ruptured cerebral aneurysm or patients who have excess cerebrospinal fluid after a lumbar puncture or surgery for tumor resection. * 18 years of age or older exclusion criteria: * patients or family who are unable to understand the informed consent process will be excluded.
tolerance and potential synergistic effect of the combination of intranasal esketamine and non-selective maoi

Conditions: Depression Anxiety Disorder

Summary: there are already recently published data on the tolerability and efficacy of the combination of ketamine and/or esketamine with maois. however, these reports are few and far between, and to our knowledge, there are no data involving intranasal esketamine. given the numerous interactions between maois and other antidepressants, and the impossibility of combination, this pharmacological class is neglected. this is despite the fact that maois are the only truly tri-aminergic drugs, that they have unparalleled efficacy in certain forms of resistant apathetic depression, and that new, more dietary permissive forms have appeared on the market. the arrival of antidepressants that can be combined with maois, such as ketamine and esketamine, changes the situation and could offer a new treatment opportunity to many patients in a therapeutic impasse. for these opportunities to become a reality, sharing the clinical experience gained by specialized centers is essential.


Eligibility criteria:
inclusion criteria: * major subject. * having been treated with intranasal esketamine between 01/01/2018 and 01/03/2022. * not objecting to the reuse of their data for scientific research purposes. exclusion criteria: - subject who has expressed opposition to the reuse of their data for scientific research purposes.

Keywords: depression disorder anxiety disorder intranasal esketamine monoamine oxidase inhibitors (maois) maois antidepressants ketamine
gemcitabine in nk/t cell lymphoma

Conditions: NK/T Cell Lymphoma

Summary: we retrospectively review patients with refractory or relapsed enkl who received a gemcitabine-containing regimen


Eligibility criteria:
inclusion criteria: * nk/t cell lymphoma * relapse or refractory disease * gemcitabine containing treatment exclusion criteria:
patient navigation for medicaid frequent ed users

Conditions: Chronic Illness

Summary: a large proportion of frequent ed users have medicaid insurance. the purpose of this study is to evaluate the effectiveness of patient navigation for reducing emergency department (ed) visits and hospitalizations and improving patient-centered outcomes (e.g., self-reported health status, quality of life, access/barriers to care) among medicaid patients who are high utilizers of the ed, as well as to identify best practices for engaging and providing healthcare services to underserved patients using patient navigation. this study will address needs that have been identified within the new haven community and the local healthcare system, contribute to knowledge and literature surrounding the use of patient navigation to improve care for underserved patients and improve health system efficiency, and inform the design and development of programs that address these needs both locally and in other communities.


Eligibility criteria:
inclusion criteria: * 4-18 ed visits per year * frequent ed users * age 18 to 62 * medicaid insurance only * those living in the greater new haven area (i.e. having a zip code that matches that) exclusion criteria: * the current visit for primary psychiatric or substance abuse * more than 50% of all ed visits in the past year for primary psychiatric or substance abuse.

Keywords: healthcare utilization ed utilization primary care utilization patient navigation underserved populations health disparities
clinical-immunological features of anti-nmdar encephalitis

Conditions: Anti NMDA Receptor Encephalitis

Summary: using a retrospective cohort of 501 patients with anti-nmdar encephalitis to assess clinical and immunological prognostic biomarkers


Eligibility criteria:
inclusion criteria: * patient with neurological disorder * patient with nmdar antibodies in sera or csf exclusion criteria: * - no available clinical data * patient without nmdar antibodies or neurological disorder

Keywords: anti nmda receptor encephalitis antibodies relapses outcomes
the mechanisms and significances of synergistic effects of mycophenolic acid and lps on il-1β secretion by mononuclear

Conditions: Lupus Nephritis

Summary: to determine the mechanisms and significances of synergistic effects of mycophenolic acid and lps on il-1β secretion by mononuclear

mycophenolate mofetil (mmf), which inhibits t and b lymphocyte proliferation, is widely used to treat a variety of autoimmune diseases, such as systemic lupus erythematosus (sle) and lupus nephritis (ln). we are the first to show that mycophenolic acid (mpa), the active metabolite of mmf, in association with lipopolysaccharide (lps), is able to promote the secretion of interleukin (il)-1β, which contradicts the traditional conception that immunosuppressants inhibit the secretion of inflammatory factors. in this study, we first determined the effects of mpa in association with lps on il-1β production. then, we explored whether the synergized effect on il-1β production was mediated through the nuclear factor （nf）-κb pathway that produces more pro-il-1β, or through the triggering of nlrp3 inflammasome that leads to enhanced activation of caspase-1 and accelerated degradation of pro-il-1β into mature il-1β. this study is not only conducive to clarify the mechanisms, signal transduction pathways and potential clinical significances of il-1β production in lps and mpa combined treatment, but also to provide experimental data as well as theoretical rationales for more effective and more logical immunosuppressive protocols.

Eligibility criteria:
inclusion criteria: * healthy volunteers，age 18-60. exclusion criteria: * don't agree with informed consent
a study of ly3972406 in adult participants with moderate-to-severe plaque psoriasis

Conditions: Plaque Psoriasis

Summary: the main purpose of this study is to determine the efficacy and safety of ly3972406 in adult participants with moderate-to-severe plaque psoriasis.


Eligibility criteria:
inclusion criteria: * have moderate-to-severe chronic plaque psoriasis for at least 6 months prior to baseline * have venous access sufficient to allow for blood sampling * are able to swallow oral medication exclusion criteria: * have any other skin conditions, excluding plaque psoriasis * have a current or recent acute, active infection * have manifestations of other autoimmune diseases, such as systemic lupus erythematosus. * are lactating or breastfeeding women
dose response study of patients with erythematous rosacea

Conditions: Erythematous (Type One) Rosacea

Summary: the purpose of this study is to evaluate the dose-response relationship (effect) of four concentrations of v-101 cream in patients with erythematous(redness) rosacea.

patients must have moderate to severe erythematous (facial redness) rosacea * male and female patients must be at least 18 years old and in good general health * female patients must not be pregnant or nursing

Eligibility criteria:
inclusion criteria: * male or females at least 18 years of age * diagnosis of stable erythematous rosacea * \< 3 inflammatory lesions * in good general health * females must be non-pregnant and non-lactating * must be willing to sign a consent form exclusion criteria: * have ocular, phymatous or other types of rosacea * allergy to any ingredient in study drug * participation in other investigational studies within 30 days of enrollment * use of systemic steroids within 28 days of baseline * use of tetracycline antibiotics within 28 days of baseline * use of products containing oxymetazoline within 14 days of baseline * use of topical steroids witin treatment area 14 days prior to baseline * use of rx or otc products for treatment of acne or rosacea within 14 days of baseline * use of any product for reducing redness within the treatment area witin 14 days prior to baseline * use of monoamine oxidase (mao) inhibitors * use of niacin \>/= 500mg/day

Keywords: rosacea, erythema
self-management support in cancer pain

Conditions: Pain

Summary: pain is a prevalent and distressing symptom in patients with cancer, having an enormous impact on functioning and quality of life. integration of patient self-management and professional care by means of care technology provides new opportunities in the outpatient setting. in this project a technology based and nurse delivered multicomponent self-management support intervention has been developed. important components include monitoring, feedback, education, and nurse support. following feasibility evaluation, the primary aim of this randomized controlled trial is to assess the effect of the intervention regarding pain intensity and quality of life as compared to care as usual. secondary outcomes of the effect evaluation are self-efficacy, knowledge, anxiety and depression, and pain medication use. besides, a cost-evaluation and summative process evaluation will be performed.


Eligibility criteria:
inclusion criteria: * diagnosis of cancer * patients who are under (palliative) anti-tumour treatment in a day clinic or outpatient clinic, or patients who have no treatment options available anymore * cancer (treatment related) pain \> 2 weeks * pain is defined as a patient reported pain score of 4 or more on a numerical rating scale (scale 0-10) * living at home exclusion criteria: * expected life expectancy \< 3 months * chronic non-cancer pain * known cognitive impairments * participation in other studies that interfere with this study * not being able to read and understand the dutch language * reduced vision * non-reachable by phone

Keywords: cancer pain self-management randomized controlled trial
a multicenter, prospective, randomized, double-blind clinical trial comparing itraconazole oral solution in cyclodextrin to placebo in the treatment of aspergilloma

Conditions: Aspergillosis; Lung Diseases, Fungal

Summary: to compare the safety and effectiveness of itraconazole oral solution to placebo in the treatment of a pulmonary aspergilloma. aspergilloma is a "fungal ball" in the lungs caused by aspergillus. the infection can spread from the lungs through the blood to other organs. aspergilloma can be life-threatening; therefore, an effective treatment is needed.

patients are randomly selected to receive itraconazole oral solution by mouth or the inactive placebo (oral cyclodextrin solution) twice daily for 12 months.

Eligibility criteria:
inclusion criteria: you may be eligible for this study if you: * are 18 years of age or older. * have been diagnosed with aspergilloma within the last month. * have (or have a history of) at least one of the following: 1. positive test for aspergillus species. 2. presence of antibodies to aspergillus. * are willing to participate in the study for 2 full years. * are female and not pregnant. * are not breast-feeding. * agree to use barrier methods of birth control / contraception during the study and for 30 days after. exclusion criteria: you will not be eligible for this study if you: * have a history of allergy to triazole or imidazole drugs. * are unable to take oral medication. * are not expected to live for more than a month. * have had a lung biopsy indicating aspergillus infection. * have had radiation therapy within the last 6 months. * require treatment with certain medications. * received amphotericin, amphotericin lipid formulation, fluconazole, or itraconazole in the two weeks prior to study entry. * received chemotherapy within the last 6 months.
mind-body interventions in cardiac patients

Conditions: Acute Coronary Syndrome; Congestive Heart Failure

Summary: this study is investigating whether a series of psychological exercises, called positive psychology, provides benefit to patients who have been hospitalized for heart disease (an 'acute coronary syndrome' or heart failure). in this study, subjects are randomly assigned to complete 8 positive psychology exercises over 8 weeks, or to complete different exercises in control groups. we hypothesize that patients who are assigned to the positive psychology tasks will be able to complete the exercises at a high rate, will feel that the exercises were easy to perform, and will have greater improvements of optimism, anxiety, mood, and health-related quality of life than subjects in the control conditions.


Eligibility criteria:
inclusion criteria: * hospitalization at massachusetts general hospital for an acute coronary syndrome or congestive heart failure * able to read/write in english * have working home or cellular phone exclusion criteria: * cognitive disorder * medical condition likely to lead to death within 6 months * illness leading to inabilty to consent or complete study exercises * current or prior participation in positive psychology interventions

Keywords: positive psychology cardiovascular disease
a study of the safety and efficacy of synvisc in patients with symptomatic ankle osteoarthritis

Conditions: Osteoarthritis

Summary: this clinical study is to evaluate the safety and efficacy of synvisc in patients with symptomatic ankle osteoarthritis (oa). patients will be given synvisc, with the possible administration of a second injection where insufficient symptomatic pain relief was experienced during the initial 3 months follow up period.


Eligibility criteria:
inclusion criteria: * patients with symptomatic oa pain of ankle (talo-crural) exclusion criteria: * patients with current or prior conditions or treatments that would impede measurements of efficacy or safety

Keywords: osteoarthritis of the ankle musculoskeletal
study of oca in combination with bzf evaluating efficacy, safety and tolerability in participants with pbc

Conditions: Primary Biliary Cholangitis

Summary: study to determine the effect of the investigational drug bezafibrate (bzf) alone and in combination with the investigational drug obeticholic acid (oca) in participants with primary biliary cholangitis (pbc).


Eligibility criteria:
inclusion criteria: * a definite or probable diagnosis of pbc * qualifying alp and/or bilirubin liver biochemistry values * taking ursodeoxycholic acid (udca) for at least 12 months or no udca for 3 months before day 1 exclusion criteria: * history or presence of other concomitant liver diseases * presence of clinical complications of pbc * history or presence of decompensating events * current or history of gallbladder disease * if female, known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating * treatment with commercially available oca or participation in a previous study involving oca, or other farnesoid x receptor (fxr) agonists, or peroxisome proliferator activated receptor (ppar)-agonists within 3 months before screening * unable to tolerate bzf or other fibrates, treatment with commercially available fibrates, or participation in a previous study involving fibrate within 3 months before screening. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: primary biliary cholangitis primary biliary cirrhosis hepatic impairment cirrhosis liver
zoledronic acid in the treatment of breast cancer with minimal residual disease in the bone marrow

Conditions: Primary Breast Cancer

Summary: metastatic bone disease is an important prognostic factor for survival which will in median be close to two years after first diagnosis of osseous metastases. this open-label study will investigate the safety and efficacy of zoledronic acid in patients with breast cancer and minimal residual disease in the bone marrow.


Eligibility criteria:
inclusion criteria: * patients, with primary breast cancer who had undergone complete primary tumor resection and axillary lymph node dissection * evidence of minimal residual disease (disseminated tumor cells in bone marrow) * patients had to receive one of the following adjuvant therapy categories: chemotherapy ± hormonal therapy or hormonal therapy alone exclusion criteria: * inflammatory, metastatic or recurrent breast cancer or a history of breast cancer prior to the currently diagnosed case * neo-adjuvant chemotherapy, neo-adjuvant hormonal therapy, or neo-adjuvant radiotherapy * prior stem cell rescue/bone marrow transplant * history of other cancers aside from non-melanomatous skin cancer or carcinoma in situ of the uterine cervix additional protocol-defined inclusion / exclusion criteria may apply

Keywords: primary breast cancer bone metastases minimal residual disease bisphosphonates
aortopathy in persons with bicuspid aortic valve, turner and marfan syndrome

Conditions: Turner Syndrome; Bicuspid Aortic Valve; Marfan Syndrome

Summary: the study aim is: 1. to examine aortic tissue by light microscopy 2. to examine aortic tissue by electron microscopy 3. to study changes in the epigenome and transcriptome of the x chromosome specific to aortic tissue. 4. to examine aortic tissue using biochemistry including proteomics. 5. to establish the karyotype of fibroblasts with standard chromosome examination on 10 meta-phases as well as by fluorescent in situ hybridization (fish) with probes covering the x and y chromosome. using the latter 200 meta-phases will be examined. 30 controls who did not die from aortic dissection or dilation will be recruited from the department of forensic medicine at aarhus university hospital. the investigators will subject samples of aortic tissue from women undergoing prophylactic aortic surgery due to either marfan syndrome or bicuspid aortic valve to the same panel of examinations (except karyotyping). lastly the investigators will compare the results from the three groups (turner syndrome, marfan syndrome and bicuspid aortic valve).

turner syndrome is a congenital complete or partial lack of one of the female sex chromosomes affecting 1 of 2000 live born girls. the syndrome is characterized by an increased prevalence of ischemic heart disease, aortic dilation and dissection, hypertension, stroke and autoimmune diseases in general.

Eligibility criteria:
turner syndrome (ts). a. inclusion * ts verified by genotyping * age \> 18 years * awaiting operation due to aortic dilation b. exclusion - previous aortic dissection or operation of the aorta (per-cutaneous or open surgery) marfan syndrome (ms) a. inclusion * females with ms verified clinically or by genotyping * age \> 18 years * awaiting operation due to aortic dilation b. exclusion - previous aortic dissection or operation of the aorta (per-cutaneous or open surgery) bicuspid aortic valve a. inclusion * females with bicuspid aortic valve * age \> 18 years * awaiting operation due to aortic dilation b. exclusion - previous aortic dissection or operation of the aorta (per-cutaneous or open surgery) controls a. inclusion * men/females who died from conditions other than aortic dilation or dissection. * age 20-60 years. b. exclusion - previous aortic dissection or operation of the aorta (per-cutaneous or open surgery)

Keywords: sex chromosome turner syndrome marfan syndrome bicuspid aortic valve aortic aneurysm epigenetics transcriptome non-coding rna electron microscopy proteomics